Industry News — Clinical Updates

Genentech Statement on Counterfeit Drug Labeled Avastin

ASRS was notified earlier today by Genentech that a counterfeit product, labeled as Avastin (bevacizumab), has been distributed in the United States.  Genentech has indicated that the counterfeit supply has not impacted ophthalmology. 

The Food and Drug Administration is investigating and in the meantime, has issued the following statement:  "At this time, we do not have any indication that the counterfeit Avastin has reached the ophthalmic supply chain.  It remains important to carefully check any product to determine if it is FDA approved before using it." 

The ASRS has shared the attached Genentech press release providing information on how to identify the counterfeit product with the compounding pharmacies that participated in the ASRS quality survey.  Please feel free to share it with your compounding pharmacy as well and ask them to confirm that your bevacizumab supply was purchased directly from the manufacturer.

To keep apprised of the results of the FDA investigation go to:  http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/default.htm .

Read full statement from Genentech.

Posted Feb. 14, 2012

Designed and built in Chicago by Webitects